RT Journal Article SR Electronic T1 Degalactosylated/Desialylated Human Serum Containing GcMAF Induces Macrophage Phagocytic Activity and In Vivo Antitumor Activity JF Anticancer Research JO Anticancer Res FD International Institute of Anticancer Research SP 2881 OP 2885 VO 33 IS 7 A1 DAISUKE KUCHIIKE A1 YOSHIHIRO UTO A1 HIROTAKA MUKAI A1 NORIKO ISHIYAMA A1 CHIAKI ABE A1 DAICHI TANAKA A1 TOMOHITO KAWAI A1 KENTARO KUBO A1 MARTIN METTE A1 TOSHIO INUI A1 YOSHIO ENDO A1 HITOSHI HORI YR 2013 UL http://ar.iiarjournals.org/content/33/7/2881.abstract AB Background: The group-specific component protein-derived macrophage-activating factor (GcMAF) has various biological activities, such as macrophage activation and antitumor activity. Clinical trials of GcMAF have been carried out for metastatic breast cancer, prostate cancer, and metastatic colorectal cancer. In this study, despite the complicated purification process of GcMAF, we used enzymatically-treated human serum containing GcMAF with a considerable macrophage-stimulating activity and antitumor activity. Results: We detected GcMAF in degalactosylated/desialylated human serum by western blotting using an anti-human Gc globulin antibody, and Helix pomatia agglutinin lectin. We also found that GcMAF-containing human serum significantly enhanced the phagocytic activity of mouse peritoneal macrophages and extended the survival time of mice bearing Ehrlich ascites tumors. Conclusion: We demonstrated that GcMAF-containing human serum can be used as a potential macrophage activator for cancer immunotherapy.